ImmuPharma shares were down 6.4% to 5.5p in early afternoon trading on Wednesday, after the group reported a widened loss to £8.2 million in its FY 2021 results, from a £6.9 million loss in FY 2020. The lupus-focused group confirmed research and development expenses of £3.7 million against £2.4 million the last year, along with […]

The post ImmuPharama shares fall on widened £8.2m loss appeared first on UK Investor Magazine.